Abstract:Introduction: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are becoming more popular in managing type 2 diabetes mellitus (T2DM). Concerns linger over potential links to malignancies like pancreatic and thyroid cancers, requiring more research to clarify their safety profiles. Additionally, evidence suggests GLP-1 RAs may lower colorectal and pancreatic cancer risk, especially in obese and overweight individuals, indicating a protective effect beyond weight loss. Current studies leave a gap in comprehensively understanding cancer risks associated with GLP-1 RAs, which prompts further research to enhance our understanding of their overall safety. Methods: We queried the US Collaborative Network (63 health care organizations) of the TriNetX research database. Patients with T2DM were identified and divided into two cohorts: patients on GLP-1 RAs and patients not on GLP-1 RAs. We excluded tobacco use and alcohol use disorders, obese patients with a body mass index (BMI) of >25 kg/m2, and those with a family history of gastrointestinal malignancy, infectious mononucleosis, chronic gastritis, pernicious anemia, helicobacter pylori infection, or gastroesophageal reflux disease (GERD). We used a 1:1 propensity score matching (PSM) model using patients' baseline characteristics, medications, labs, and genetics. We compared the rate of gastric cancer and esophageal cancer at the seven-year mark. Results: A total of 2,748,431 patients with T2DM were identified. Of those, 6% (n = 167,077) were on a GLP-1 RA and 94% (n = 2,581,354) were not on a GLP-1 RA. After PSM, both cohorts included 146,277 patients. Patients with T2DM who were on a GLP-1 RA, compared to those who were not, had a statistically significant lower risk of both gastric cancer (0.05% vs. 0.13%, p < 0.0001) and esophageal cancer (0.04% vs. 0.13%, p < 0.0001) at the seven-year mark. Conclusion: The use of GLP-1 RAs in patients with T2DM does not significantly increase the risk of gastric or esophageal cancer. This finding supports the continued use of GLP-1 analogues as a therapeutic option in managing T2DM, considering their well-established benefits and low risk of complications. Based on the study results, these medications may even have a protective effect against these malignancies.

S2482 Prescriber Beware: Rethinking the Routine Glucagon-Like Peptide-1 Receptor Agonists

Heightened Vigilance Needed When Patients Are Prescribed GLP-1 and GIP Agonists

S2135 Prescription Patterns of Glucagon-Like Peptide-1 Receptor Agonists in the Pediatric Population

S927 Risk of Gastric Food Retention With Glucagon-like Peptide 1 Receptor Agonists versus Diabetes Mellitus: A Case-Control Study From a Large Tertiary Care Health System

Glucagon-Like Peptide-1 Receptor Agonists in Primary Care: Beyond Glycemic Control

Clinical Outcomes and Safety of Upper Endoscopy While on Glucagon-Like Peptide-1 Receptor Agonists

Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis

S727 GLP-1 RA Use in Patients with T2DM is Associated with Lower Risk of Esophageal Cancer: A National Analysis

S2097 Characteristics of Glucagon-Like Peptide-1 Receptor Agonist Mentions in Unstructured Notes of Specialty Dermatology Clinics

Glucagon-Like Peptide 1 Receptor Agonist Use in Hospital: A Multicentre Observational Study

Highway to the danger zone? A cautionary account that GLP‐1 receptor agonists may be too effective for unmonitored weight loss

Risk of Esophageal and Gastric Cancer in Patients with Type 2 Diabetes Receiving Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs): A National Analysis

Glucagon-Like Peptide-1 Receptor Agonists Increase Solid Gastric Residue Rates On Upper Endoscopy Especially In Complicated Diabetic Patients: A Case Control Study

Thyroid hyperplasia and neoplasm adverse events associated with GLP-1 receptor agonists in FDA Adverse Event Reporting System

Navigating Glucagon-Like Peptide Receptor Agonist Reinitiation Amid Access Barriers: An Adverse Drug Event Case Report

Risks of peri- and postoperative complications with glucagon-like peptide-1 receptor agonists

Glucagonlike Peptide-1 Receptor Agonists: The Good, the Bad, and the Ugly-Benefits for Glucose Control and Weight Loss with Side Effects of Delaying Gastric Emptying

Safe Continuation of Glucagon-like Peptide 1 Receptor Agonists at Endoscopy: A Case Series of 57 Adults Undergoing Endoscopic Sleeve Gastroplasty

Gastrointestinal Adverse Events of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes: a Systematic Review and Network Meta-Analysis.

Glucagon-Like Peptide 1 Receptor Agonist Usage in Type 2 Diabetes in Primary Care for the UK and Beyond: A Narrative Review

Glucagon-like-peptide-1 receptor agonists and the management of type 2 diabetes-backwards and forwards